Chemomab Therapeutics Ltd
NASDAQ:CMMB
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
Abbvie Inc
NYSE:ABBV
|
Biotechnology
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Realty Income Corp
NYSE:O
|
Real Estate
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
| US |
|
Walt Disney Co
NYSE:DIS
|
Media
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
This note will be permanently deleted.
Chemomab Therapeutics Ltd
Chemomab Therapeutics Ltd
Net Change in Cash
Chemomab Therapeutics Ltd
Net Change in Cash Peer Comparison
CLGN
KMDA
URGN
ENTX
Competitive Net Change in Cash Analysis
Latest Figures & CAGR of Competitors
| Company | Net Change in Cash | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Chemomab Therapeutics Ltd
NASDAQ:CMMB
|
Net Change in Cash
-$4.2m
|
CAGR 3-Years
-97%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Collplant Biotechnologies Ltd
NASDAQ:CLGN
|
Net Change in Cash
-$3.2m
|
CAGR 3-Years
-94%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Kamada Ltd
NASDAQ:KMDA
|
Net Change in Cash
$21.1m
|
CAGR 3-Years
20%
|
CAGR 5-Years
36%
|
CAGR 10-Years
7%
|
|
|
Urogen Pharma Ltd
NASDAQ:URGN
|
Net Change in Cash
$94.9m
|
CAGR 3-Years
89%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
N/A
|
|
|
Entera Bio Ltd
NASDAQ:ENTX
|
Net Change in Cash
-$1.3m
|
CAGR 3-Years
42%
|
CAGR 5-Years
21%
|
CAGR 10-Years
N/A
|
|
B
|
Bonus Biogroup Ltd
TASE:BONS
|
Net Change in Cash
-₪29.1m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
-135%
|
CAGR 10-Years
-63%
|
See Also
What is Chemomab Therapeutics Ltd's Net Change in Cash?
Net Change in Cash
-4.2m
USD
Based on the financial report for Dec 31, 2023, Chemomab Therapeutics Ltd's Net Change in Cash amounts to -4.2m USD.
What is Chemomab Therapeutics Ltd's Net Change in Cash growth rate?
Net Change in Cash CAGR 3Y
-97%
Over the last year, the Net Change in Cash growth was -156%. The average annual Net Change in Cash growth rates for Chemomab Therapeutics Ltd have been -97% over the past three years .
You don't have any saved screeners yet
